ARCHIVES

IL-2 Trials Proliferate; Biotherapeutics Sees NCI Proposal As Vindication Of Its Policies

This article is from The Cancer Letter archive.

Vol. 13 No. 19 | May 8, 1987

Download PDF Visit The Full Archive

Related Articles

Report Urges Better Working Conditions For Postdocs.

October 6, 2000

Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial

January 27, 2012

New ACS Awards Total $18.4 Million

February 23, 1979

“Unfortunate Result Of Burzynski’s Practice Over Two Decades: Thousands Of Patients, Not Enough Data” To Determine Safety, Efficacy, FDA Says

September 25, 1998

Circulating Tumor Cells Predict Treatment Resistance In Study Of Metastatic Breast Cancer

August 30, 2013

NCI Plans Two New RFAs For Stimulus Funds

March 6, 2009